PHASE 11 TRIAL OF LJP 394 IN PATIENTS WITH SLE

$0M01FY2000RRNIH

Medical University Of South Carolina, Charleston SC

Investigators

Linked publications & trials

Paper 38622506 Paper 37216969 Paper 36203085 Paper 35271380 Paper 35196139 Paper 35169056 Paper 34008864 Paper 32814855 Paper 32675856 Paper 32664257 Paper 31747417 Paper 31665727 Paper 31434620 Paper 31182728 Paper 31106972 Paper 31028056 Paper 29873771 Paper 29784706 Paper 29551311 Paper 29122892 Paper 28867355 Paper 28549637 Paper 27099075 Paper 26867033 Paper 26554936 Paper 26416936 Paper 26351776 Paper 25912764 Paper 25623616 Paper 25448734 Paper 25290343 Paper 25028567 Paper 24796291 Paper 24685959 Paper 24560422 Paper 24154674 Paper 24106214 Paper 23950187 Paper 23850262 Paper 23835761 Paper 23806832 Paper 23667346 Paper 23637325 Paper 23557538 Paper 23531957 Paper 23415658 Paper 23396174 Paper 23393212 Paper 23314242 Paper 23131462 Paper 23104969 Paper 22963984 Paper 22900949 Paper 22766231 Paper 22525442 Paper 22521363 Paper 22494223 Paper 22438226 Paper 22428349 Paper 22269205 Paper 22222338 Paper 22141359 Paper 22088620 Paper 21949144 Paper 21774138 Paper 21722152 Paper 21710170 Paper 21706518 Paper 21498785 Paper 21435288 Paper 21422385 Paper 21392193 Paper 21306838 Paper 21276755 Paper 21274703 Paper 21249401 Paper 21197089 Paper 21143244 Paper 21129757 Paper 20934835 Paper 20924284 Paper 20863528 Paper 20851531 Paper 20817935 Paper 20723641 Paper 20672296 Paper 20653639 Paper 20603872 Paper 20570051 Paper 20566951 Paper 20549728 Paper 20507373 Paper 20506234 Paper 20461784 Paper 20444266 Paper 20394942 Paper 20391862 Paper 20206451 Paper 20201901 Paper 20180689

Abstract

The primary objective of this trial is to evaluate the long-term safety and efficacy of different doses of LJP 394 patients with a diagnosis of SLE. Efficacy parameters to be evaluated during the trial include: changes in anti-dsDNA antibody concentrations as measured by the Farr and Elisa methodologies, concomitant medications, changes in complement (C3,C4) results of the Systemic Lupus Erythematosus Disease Activity Index (SLEDAI) assessment of clinical status, the MOS SF-36 Survey and the changes in renal function parameters Time to Renal Flare will also be evaluated

View original record on NIH RePORTER →